A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Niger, Monica; Nichetti, Federico; Fornaro, Lorenzo; Pircher, Chiara; Morano, Federica; Palermo, Federica; Rimassa, Lorenza; Pressiani, Tiziana; Berardi, Rossana; Gardini, Andrea Casadei; Sperti, Elisa; Salvatore, Lisa; Melisi, Davide; Bergamo, Francesca; Siena, Salvatore; Mosconi, Stefania; Longarini, Raffaella; Arcangeli, Giuseppina; Corallo, Salvatore; Delliponti, Laura; Tamberi, Stefano; Fea, Elena; Brandi, Giovanni; Rapposelli, Ilario Giovanni; Salati, Massimiliano; Baili, Paolo; Miceli, Rosalba; Ljevar, Silva; Cavallo, Ilaria; Sottotetti, Elisa; Martinetti, Antonia; Busset, Michele Droz Dit; Sposito, Carlo; Di Bartolomeo, Maria; Pietrantonio, Filippo; de Braud, Filippo; Mazzaferro, Vincenzo

doi:10.1186/s12885-024-12225-6

BMC Cancer

Article metrics
Last updated: Fri, 17 May 2024 6:42:43 Z

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Access & Citations

637

Article Accesses
0

Web of Science
1

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com